Information Provided By: 
Fly News Breaks for November 5, 2015
GILD, AMGN, BIIB, ISIS
Nov 5, 2015 | 06:21 EDT
Piper Jaffray analyst Joshua Schimmer upgraded Isis Pharmaceuticals (ISIS) to Overweight citing the company's pipeline progress and his increasing confidence in the antisense platform. Schimmer calls the latest update from Biogen (BIIB) for the shared SMN-Rx program for spinal muscular atrophy "very encouraging." He believes the product could make a very attractive in-licensing candidate for Amgen (AMGN) or Gilead (GILD). The analyst raised his price target for Isis to $80 from $64.
News For ISIS;BIIB;AMGN;GILD From the Last 2 Days
